Clinical Efficacy of Bendamustine Plus Rituximab (BR) for B-cell Relevant Indolent Non-Hodgkin's Lymphoma and Role of β2-MG in Predicting the Efficacy of BR Regimen: A Real-World Retrospective Study in China

BACKGROUND: Domestic bendamustine has been approved for appearing on the market in China in the past two years. The report on bendamustine plus rituximab (BR) in the treatment of Chinese B-cell-associated indolent non-Hodgkin's lymphoma (iNHL) has not yet been published. This study probed into...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Yujie, He, Donghua, He, Jingsong, Huang, Weijia, Yang, Yang, Cai, Zhen, Zhao, Yi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8794694/
https://www.ncbi.nlm.nih.gov/pubmed/35096126
http://dx.doi.org/10.1155/2022/1080879

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8794694/
https://www.ncbi.nlm.nih.gov/pubmed/35096126
http://dx.doi.org/10.1155/2022/1080879

Ejemplares similares